ATE378407T1 - Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen - Google Patents
Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungenInfo
- Publication number
- ATE378407T1 ATE378407T1 AT95918920T AT95918920T ATE378407T1 AT E378407 T1 ATE378407 T1 AT E378407T1 AT 95918920 T AT95918920 T AT 95918920T AT 95918920 T AT95918920 T AT 95918920T AT E378407 T1 ATE378407 T1 AT E378407T1
- Authority
- AT
- Austria
- Prior art keywords
- morphogen
- methods
- cell surface
- surface receptors
- identifying
- Prior art date
Links
- 108010001857 Cell Surface Receptors Proteins 0.000 title abstract 3
- 102000006240 membrane receptors Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- 102000005962 receptors Human genes 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 abstract 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23642894A | 1994-04-29 | 1994-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378407T1 true ATE378407T1 (de) | 2007-11-15 |
Family
ID=22889467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95918920T ATE378407T1 (de) | 1994-04-29 | 1995-04-28 | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US5863738A (de) |
| EP (1) | EP0756628B1 (de) |
| JP (1) | JPH10511840A (de) |
| AT (1) | ATE378407T1 (de) |
| AU (1) | AU702163B2 (de) |
| CA (1) | CA2187902A1 (de) |
| DE (1) | DE69535641D1 (de) |
| WO (1) | WO1995030003A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69332779T2 (de) * | 1992-11-17 | 2003-10-23 | Ludwig Institut For Cancer Research, Padington | Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen |
| AU709991B2 (en) * | 1995-08-14 | 1999-09-09 | Creative Biomolecules, Inc. | Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof |
| US20040002117A1 (en) * | 1998-02-12 | 2004-01-01 | Hogan Patrick G. | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
| JP4892131B2 (ja) † | 1998-11-13 | 2012-03-07 | ストライカー コーポレイション | 癌の症状を緩和する方法 |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| CA2431035A1 (en) * | 2000-11-06 | 2002-05-10 | Thrasos, Inc. | Computer method and apparatus for classifying objects |
| ATE354802T1 (de) * | 2000-11-06 | 2007-03-15 | Thrasos Inc | Methoden zum screening knochenmorphogenetishemimetika |
| MXPA04003697A (es) * | 2001-10-31 | 2005-04-08 | Alcon Inc | Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma. |
| AU2003221841A1 (en) | 2002-04-03 | 2003-10-27 | Celltech R And D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| EA015166B1 (ru) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител |
| JP4971149B2 (ja) | 2004-06-17 | 2012-07-11 | スラソス セラピューティックス インコーポレーテッド | Ｔｄｆ関連化合物およびその類似体 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| DK1904093T3 (en) * | 2005-07-19 | 2018-09-03 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with BMP-4 |
| JP2009508532A (ja) | 2005-09-20 | 2009-03-05 | スラソス セラピューティックス インコーポレーテッド | Ｔｄｆ関連化合物およびその類似体 |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| EP3811965A1 (de) * | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonisten zur verwendung in der förderung von knochenwachstum |
| CA2649770C (en) | 2006-04-18 | 2017-08-15 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop) |
| US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| ES2449753T3 (es) * | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CA2997971A1 (en) | 2008-11-26 | 2010-06-03 | Amgen Inc. | Variants of activin iib receptor polypeptides and uses thereof |
| KR101805201B1 (ko) | 2009-03-30 | 2017-12-05 | 악셀레론 파마 인코포레이티드 | Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도 |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| AU2012236962B2 (en) | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| ES2667554T3 (es) | 2011-08-04 | 2018-05-11 | Amgen Inc. | Método para el tratamiento de los defectos de espacio óseo |
| AU2012364736A1 (en) | 2011-12-19 | 2014-07-24 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| AU2012362898B2 (en) | 2011-12-28 | 2017-11-09 | Amgen, Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MX2015009901A (es) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administración de un compuesto de antiactivina a a un sujeto. |
| FR3024462A1 (fr) * | 2014-07-29 | 2016-02-05 | Univ Pierre Et Marie Curie Paris 6 | Procede de production in vitro de progeniteurs adipocytaires et d'adipocytes |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| CA3117323A1 (en) | 2018-10-22 | 2020-04-30 | William D. Carlson | Therapeutic combinations of tdfrps and additional agents and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011366A1 (en) * | 1989-03-28 | 1990-10-04 | Genetics Institute, Inc. | Osteoinductive compositions |
| GB8827367D0 (en) | 1988-11-23 | 1988-12-29 | Lawrence C A | Spinning of yarn |
| CA2042577A1 (en) * | 1989-10-17 | 1991-04-18 | Hermann Oppermann | Osteogenic devices |
| EP1033574A3 (de) * | 1991-08-30 | 2004-01-28 | Curis, Inc. | Screeningverfahren von morphogenischen Proteinen |
| AU3920693A (en) * | 1992-03-18 | 1993-10-21 | General Hospital Corporation, The | Four novel receptors of the TGF-beta receptor family |
| DE4225427A1 (de) * | 1992-07-31 | 1994-02-03 | Boehringer Mannheim Gmbh | Verfahren zur Gewinnung rekombinanter, biologisch aktiver, eukaryontischer alkalischer Phosphatase |
| DE69332779T2 (de) * | 1992-11-17 | 2003-10-23 | Ludwig Institut For Cancer Research, Padington | Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen |
| US6291206B1 (en) * | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| US6248554B1 (en) * | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
-
1995
- 1995-04-28 EP EP95918920A patent/EP0756628B1/de not_active Expired - Lifetime
- 1995-04-28 WO PCT/US1995/005467 patent/WO1995030003A2/en not_active Ceased
- 1995-04-28 JP JP7528497A patent/JPH10511840A/ja not_active Withdrawn
- 1995-04-28 DE DE69535641T patent/DE69535641D1/de not_active Expired - Lifetime
- 1995-04-28 AU AU24662/95A patent/AU702163B2/en not_active Expired
- 1995-04-28 US US08/481,337 patent/US5863738A/en not_active Expired - Lifetime
- 1995-04-28 CA CA002187902A patent/CA2187902A1/en not_active Abandoned
- 1995-04-28 AT AT95918920T patent/ATE378407T1/de not_active IP Right Cessation
- 1995-06-02 US US08/448,371 patent/US6632618B1/en not_active Expired - Lifetime
-
2001
- 2001-10-18 US US09/982,543 patent/US7067260B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 US US11/098,889 patent/US20050233379A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020155500A1 (en) | 2002-10-24 |
| CA2187902A1 (en) | 1995-11-09 |
| EP0756628B1 (de) | 2007-11-14 |
| WO1995030003A2 (en) | 1995-11-09 |
| US7067260B2 (en) | 2006-06-27 |
| DE69535641D1 (de) | 2007-12-27 |
| AU2466295A (en) | 1995-11-29 |
| EP0756628A1 (de) | 1997-02-05 |
| US20050233379A1 (en) | 2005-10-20 |
| JPH10511840A (ja) | 1998-11-17 |
| US5863738A (en) | 1999-01-26 |
| AU702163B2 (en) | 1999-02-18 |
| US6632618B1 (en) | 2003-10-14 |
| WO1995030003A3 (en) | 1995-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE378407T1 (de) | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen | |
| NZ500253A (en) | Osteoprotegerin binding proteins and receptors | |
| EP2311955A3 (de) | Osteoprotegerin bindende Proteine und deren Rezeptoren | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| NZ502391A (en) | Mammalian cytokine: interleukin-B30 and related reagents | |
| NO995458D0 (no) | Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder | |
| DE69838254D1 (de) | Zwei menschliche g-protein-gekoppelte rezeptorproteine: ebv-induzierter gpcr2 (ebi-2) und egd-1-ähnlicher gpcr | |
| DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
| ES2137931T3 (es) | Proteinas gdf-1 y uog-1. | |
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| WO1997007135A3 (en) | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof | |
| ATE226216T1 (de) | Netrinrezeptoren | |
| BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
| DE69735716D1 (de) | Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda | |
| EP1005539A4 (de) | Ikk-alpha proteine, nukleinsäuren und verfahren | |
| AU7017494A (en) | Purified mammalian flt3 ligands and agonists and antagonists thereof | |
| DK0833948T3 (da) | Tyktarmspecifikt gen og protein | |
| DE69925116D1 (de) | Neue, physiologisch aktive peptide und ihre verwendung. | |
| SE9602822D0 (sv) | New receptor | |
| EP0846763A3 (de) | R5, ein Protein Phosphatase-1 bindendes Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |